Item 16. Form 10-K Summary.

30K characters. Original on sec.gov · Markdown

Item 16. Form 10-K Summary.

None.

94 |

EXHIBITS

The exhibits listed below and designated with a † are filed with this report. The exhibits listed below and not so designated are incorporated by reference to the documents following the descriptions of the exhibits.


Exhibit 3.1						Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to Zoetis Inc.'s Current
						Report on Form 8-K filed on May 20, 2022 (File No. 001-35797))
Exhibit 3.2						By-laws of the Registrant, amended and restated as of December 8, 2022 (incorporated by reference to Exhibit 3.2 to Zoetis
						Inc.’s Current Report on Form 8-K filed on December 8, 2022 (File No. 001-35797))
Exhibit 4.1						Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to Zoetis Inc.'s Annual Report on Form 10-K
						filed on February 15, 2022 (File No. 001-35797))
Exhibit 4.2						Indenture, dated as of January 28, 2013, between Zoetis Inc. and Deutsche Bank Trust Company Americas, as trustee
						(incorporated by reference to Zoetis Inc.'s registration statement on Form S-1 (File No. 333-183254))
Exhibit 4.3						First Supplemental Indenture, dated as of January 28, 2013, between Zoetis Inc. and Deutsche Bank Trust Company
						Americas, as trustee (incorporated by reference to Exhibit 4.3 of Zoetis Inc.'s registration statement on Form S-1
						(File No. 333-183254))
Exhibit 4.4						Second Supplemental Indenture, dated November 13, 2015, between Zoetis Inc. and Deutsche Bank Trust Company
						Americas, as trustee (incorporated by reference to Exhibit 4.2 to Zoetis Inc.’s Current Report on Form 8-K filed on
						November 13, 2015 (File No. 001-35797))
Exhibit 4.5						Third Supplemental Indenture, dated September 12, 2017, between Zoetis Inc. and Deutsche Bank Trust Company Americas,
						as trustee (incorporated by reference to Exhibit 4.2 to Zoetis Inc.’s Current Report on Form 8-K filed on September 12, 2017
						(File No. 001-35797))
Exhibit 4.6						Fourth Supplemental Indenture, dated August 20, 2018, between Zoetis Inc. and Deutsche Bank Trust Company Americas,
						as trustee (incorporated by reference to Exhibit 4.2 to Zoetis Inc.’s Current Report on Form 8-K filed on August 20, 2018
						(File No. 001-35797))
Exhibit 4.7						Fifth Supplemental Indenture, dated May 12, 2020, between Zoetis Inc. and Deutsche Bank Trust Company Americas,
						as trustee (incorporated by reference to Exhibit 4.2 to Zoetis Inc.'s Current Report on Form 8-K filed on May 12, 2020
						(File No. 001-35797))
Exhibit 4.8						Sixth Supplemental Indenture, dated November 16, 2022, between Zoetis Inc. and Deutsche Bank Trust Company Americas,
						as trustee (incorporated by reference to Exhibit 4.2 to Zoetis Inc.’s Current Report on Form 8-K filed on November 16, 2022
						(File No. 001-35797))
Exhibit 4 .9						Form of 3.250% Senior Notes due 2023 (incorporated by reference to Exhibit 4.3 of Zoetis Inc.'s registration statement on
						Form S-1 (File No. 333-183254))
Exhibit 4.10						Form of 4.500% Senior Notes due 2025 (incorporated by reference to Exhibit 4.2 to Zoetis Inc.’s Current Report on
						Form 8-K filed on November 13, 2015 (File No. 001-35797))
Exhibit 4.1 1						Form of 4.700% Senior Notes due 2043 (incorporated by reference to Exhibit 4.3 of Zoetis Inc.'s registration statement on
						Form S-1 (File No. 333-183254))
Exhibit 4.1 2						Form of 3.000% Senior Notes due 2027 (incorporated by reference to Exhibit 4.2 to Zoetis Inc.’s Current Report on Form 8-K
						filed on September 12, 2017 (File No. 001-35797))
Exhibit 4.1 3						Form of 3.950% Senior Notes due 2027 (incorporated by reference to Exhibit 4.2 to Zoetis Inc.’s Current Report on Form 8-K
						filed on September 12, 2017 (File No. 001-35797))
Exhibit 4.1 4						Form of 3.900% Senior Notes due 2028 (incorporated by reference to Exhibit 4.2 to Zoetis Inc.’s Current Report on Form 8-K
						filed on August 20, 2018 (File No. 001-35797))
Exhibit 4.1 5						Form of 4.450% Senior Notes due 2048 (incorporated by reference to Exhibit 4.2 to Zoetis Inc.’s Current Report on Form 8-K
						filed on August 20, 2018 (File No. 001-35797))
Exhibit 4.16						Form of 2.000% Senior Notes due 2030 (incorporated by reference to Exhibit 4.2 to Zoetis Inc.’s Current Report on Form 8-K
						filed on May 12, 2020 (File No. 001-35797))
Exhibit 4.1 7						Form of 3.000% Senior Notes due 2050 (incorporated by reference to Exhibit 4.2 to Zoetis Inc.’s Current Report on Form 8-K
						filed on May 12, 2020 (File No. 001-35797))

95 |


Exhibit 4.18						Form of 5.400% Senior Notes due 2025 (incorporated by reference to Exhibit 4.3 to Zoetis Inc.’s Current Report on Form 8-K
						filed on November 16, 2022 (File No. 001-35797))
Exhibit 4.19						Form of 5.600% Senior Notes due 2032 (incorporated by reference to Exhibit 4.4 to Zoetis Inc.’s Current Report on Form 8-K
						filed on November 16, 2022 (File No. 001-35797))
Exhibit 4.20						Description of the Registrant’s Securities †
Exhibit 10.1						Global Separation Agreement, dated February 6, 2013, by and between Zoetis Inc. and Pfizer Inc. (incorporated by reference to
						Exhibit 10.1 to Zoetis Inc.’s 2012 Annual Report on Form 10-K filed on March 28, 2013 (File No. 001-35797))
Exhibit 10.2						Tax Matters Agreement, dated February 6, 2013, by and between Zoetis Inc. and Pfizer Inc. (incorporated by reference to
						Exhibit 10.3 to Zoetis Inc.’s 2012 Annual Report on Form 10-K filed on March 28, 2013 (File No. 001-35797))
Exhibit 10.3						Research and Development Collaboration and License Agreement, dated February 6, 2013, by and between Zoetis Inc.
						and Pfizer Inc. (incorporated by reference to Exhibit 10.4 to Zoetis Inc.’s 2012 Annual Report on Form 10-K filed on
						March 28, 2013 (File No. 001-35797))
Exhibit 10.4						Pfizer Inc. 2004 Stock Plan, as amended and restated (incorporated by reference to Exhibit 10.6 of Zoetis Inc.'s registration
						statement on Form S-1 (File No. 333-183254))*
Exhibit 10.5						Patent and Know-How License Agreement (Zoetis as licensor), dated February 6, 2013, by and between Zoetis Inc. and
						Pfizer Inc. (incorporated by reference to Exhibit 10.8 to Zoetis Inc.’s 2012 Annual Report on Form 10-K filed on
						March 28, 2013 (File No. 001-35797))
Exhibit 10.6						Patent and Know-How License Agreement (Pfizer as licensor), dated February 6, 2013, by and between Zoetis Inc. and
						Pfizer Inc. (incorporated by reference to Exhibit 10.9 to Zoetis Inc.’s 2012 Annual Report on Form 10-K filed on
						March 28, 2013 (File No. 001-35797))
Exhibit 10.7						Trademark and Copyright License Agreement, dated February 6, 2013, by and between Zoetis Inc. and Pfizer Inc.
						(incorporated by reference to Exhibit 10.10 to Zoetis Inc.’s 2012 Annual Report on Form 10-K filed on March 28, 2013
						(File No. 001-35797))
Exhibit 10.8						Environmental Matters Agreement, dated February 6, 2013, by and between Zoetis Inc. and Pfizer Inc. (incorporated by
						reference to Exhibit 10.13 to Zoetis Inc.’s 2012 Annual Report on Form 10-K filed on March 28, 2013) (File No. 001-35797))
Exhibit 10.9						Zoetis Inc. 2013 Equity and Incentive Plan, as amended and restated as of May 19, 2022 (incorporated by reference to Exhibit
						10.1 to Zoetis Inc.’s Quarterly Report on Form 10-Q filed on August 4, 2022 (File No. 001-35797))*
Exhibit 10.10						Sale of Business Severance Plan (incorporated by reference to Exhibit 10.17 to Zoetis Inc.’s 2012 Annual Report on
						Form 10-K filed on March 28, 2013 (File No. 001-35797))*
Exhibit 10.11						Revolving Credit Agreement, dated as of December 21, 2022, among Zoetis Inc., the lenders party thereto and JPMorgan
						Chase Bank, N.A., as administrative agent (incorporated by reference to Exhibit 10.1 of Zoetis Inc.'s Current Report
						on Form 8-K filed on December 21, 2022 (File No. 001-35797))
Exhibit 10.12						Form of Indemnification Agreement for directors and officers (incorporated by reference to Exhibit 10.19 of Zoetis Inc's
						registration statement on Form S-1 (File No. 333-183254))
Exhibit 10.13						Form of Restricted Stock Unit Award agreement (incorporated by reference to Exhibit 10.21 to Zoetis Inc.’s 2012 Annual
						Report on Form 10-K filed on March 28, 2013 (File No. 001-35797))*
Exhibit 10.14						Form of Stock Option Award agreement (incorporated by reference to Exhibit 10.22 to Zoetis Inc.’s 2012 Annual Report
						on Form 10-K filed on March 28, 2013 (File No. 001-35797))*
Exhibit 10.15						Form of Non-Employee Director Deferred Stock Unit Award agreement (incorporated by reference to Exhibit 10.23
						on Form 10-K filed on March 28, 2013 (File No. 001-35797))*
Exhibit 10.16						Form of Cash Award agreement (incorporated by reference to Exhibit 10.24 to Zoetis Inc.’s 2012 Annual Report on
						Form 10-K filed on March 28, 2013 (File No. 001-35797))*
Exhibit 10.17						Form of Performance Restricted Stock Unit Award Agreement, effective as of February 27, 2015 (incorporated by
						reference to Exhibit 99.1 to Zoetis Inc.’s Current Report on Form 8-K filed on March 4, 2015 (File No. 001-35797))*
Exhibit 10.18						Form of Restricted Stock Unit Award Agreement, effective as of February 27, 2015 (incorporated by reference to
						Exhibit 99.2 to Zoetis Inc.’s Current Report on Form 8-K filed on March 4, 2015 (File No. 001-35797))*
Exhibit 10.19						Form of Stock Option Award Agreement, effective as of February 27, 2015 (incorporated by reference to Exhibit 99.3
						to Zoetis Inc.’s Current Report on Form 8-K filed on March 4, 2015 (File No. 001-35797))*
Exhibit 10.20						Form of Cash Award Agreement, effective as of February 27, 2015 (incorporated by reference to Exhibit 99.4 to

96 |


						Zoetis Inc.’s Current Report on Form 8-K filed on March 4, 2015 (File No. 001-35797))*
Exhibit 10.21						Zoetis Amended and Restated Non-Employee Director Deferred Compensation Plan (incorporated by reference to
						Exhibit 10.1 to Zoetis Inc.’s Quarterly Report on Form 10-Q filed on November 1, 2018 (File No. 001-35797))*
Exhibit 10.22						Zoetis Executive Severance Plan (incorporated by reference to Exhibit 10.1 to Zoetis Inc.’s Quarterly Report on Form 10-Q
						filed on August 14, 2013 (File No. 001-35797))*
Exhibit 10.23						Zoetis Supplemental Savings Plan, as amended and restated, effective September 15, 2014 (incorporated by reference to
						Exhibit 10.4 to Zoetis Inc.'s Quarterly Report on Form 10-Q filed on November 10, 2014 (File No. 001-35797))*
Exhibit 10.24						Amendment No. 1 to Zoetis Supplemental Savings Plan effective December 21, 2020 (incorporated by reference to Exhibit 10.24
						to Zoetis Inc.'s 2020 Annual Report on Form 10-K filed on February 16, 2021 (File No. 001-35797))*
Exhibit 10.25						Zoetis Equity Deferral Plan, effective November 1, 2014 (incorporated by reference to Exhibit 10.5 to Zoetis Inc.’s
						Quarterly Report on Form 10-Q filed on November 10, 2014 (File No. 001-35797))*
Exhibit 10.26						Amendment No. 1 to Zoetis Equity Deferral Plan effective December 21, 2020 (incorporated by reference to Exhibit 10.26
						to Zoetis Inc.'s 2020 Annual Report on Form 10-K filed on February 16, 2021 (File No. 001-35797))*
Exhibit 10.27						Letter Agreement dated as of October 2, 2019, by and between Juan Ramón Alaix and Zoetis Inc. (incorporated by
						reference to Exhibit 10.1 to Zoetis Inc.'s Current Report on Form 8-K filed on October 3, 2019 (File No. 001-35797))
Exhibit 10.28						Letter Agreement dated as of December 9, 2019, by and between Clinton A. Lewis, Jr. and Zoetis Inc. (incorporated by
						reference to Exhibit 10.1 to Zoetis Inc.'s Current Report on Form 8-K filed on December 12, 2019 (File No. 001-35797))
Exhibit 10.29						Offer Letter, dated as of May 6, 2021, by and between Wetteny Joseph and Zoetis Inc. (incorporated by reference to Exhibit 10.1
						to Zoetis Inc.'s Current Report on Form 8-K filed on May 11, 2021 (File No. 001-35797))*
Exhibit 10.30						Amendment No. 2 to Zoetis Supplemental Savings Plan effective May 15, 2021 (incorporated by reference to Exhibit 10.1 to
						Zoetis Inc.'s Quarterly Report on Form 10-Q filed on August 5, 2021 (File No. 001-35797))*
Exhibit 10.31						Form of Restricted Stock Unit Award Agreement, effective as of July 27, 2022 (incorporated by reference to Exhibit 10.1 to
						Zoetis Inc.’s Quarterly Report on Form 10-Q filed on November 3, 2022 (File No 001-35797))*
Exhibit 10.32						Form of Stock Option Award Agreement, effective as of July 27, 2022 (incorporated by reference to Exhibit 10.2 to Zoetis Inc.’s
						Quarterly Report on Form 10-Q filed on November 3, 2022 (File No 001-35797))*
Exhibit 10.33						Form of Performance Restricted Stock Unit Award Agreement, effective as of July 27, 2022 (incorporated by reference to Exhibit
						10.3 to Zoetis Inc.’s Quarterly Report on Form 10-Q filed on November 3, 2022 (File No 001-35797))*
Exhibit 10.34						Form of Cash Award Agreement, effective as of July 27, 2022 (incorporated by reference to Exhibit 10.1 to Zoetis Inc.’s
						Quarterly Report on Form 10-Q filed on November 3, 2022 (File No 001-35797))*
Exhibit 10.35						Form of Non-Employee Director Restricted Stock Unit Award Agreement, effective as of July 27, 2022 (incorporated by
						reference to Exhibit 10.5 to Zoetis Inc.’s Quarterly Report on Form 10-Q filed on November 3, 2022 (File No 001-35797))*
Exhibit 10.36						Form of Restricted Stock Unit Award Agreement, effective as of December 8, 2022*
Exhibit 10.37						Form of Stock Option Award Agreement, effective as of December 8, 2022*
Exhibit 10.38						Form of Performance Restricted Stock Unit Award Agreement, effective as of December 8, 2022*
Exhibit 21.1						Subsidiaries of the Registrant †
Exhibit 23.1						Consent of KPMG LLP †
Exhibit 24.1						Power of Attorney (included as part of signature page) †
Exhibit 31.1						Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 †
Exhibit 31.2						Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 †
Exhibit 32.1						Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the
						Sarbanes-Oxley Act of 2002 ††
Exhibit 32.2						Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the
						Sarbanes-Oxley Act of 2002 ††
EX-101.INS						Inline XBRL INSTANCE DOCUMENT
EX-101.SCH						Inline XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
EX-101.CAL						Inline XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
EX-101.LAB						Inline XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
EX-101.PRE						Inline XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

97 |


EX-101.DEF						Inline XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
EX-104						Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)


†			Filed herewith
††			Furnished herewith
*			Management contracts or compensatory plans or arrangements

98 |

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	Zoetis Inc.
Dated: February 14, 2023	By:	/S/ KRISTIN C. PECK
		Kristin C. Peck Chief Executive Officer and Director

We, the undersigned directors and officers of Zoetis Inc., hereby severally constitute Kristin C. Peck and Heidi C. Chen, and each of them singly, our true and lawful attorneys with full power to them and each of them to sign for us, in our names in the capacities indicated below, any and all amendments to this Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.


Name		Title	Date

/S/ KRISTIN C. PECK		Chief Executive Officer and Director	February 14, 2023
Kristin C. Peck	(Principal Executive Officer)

/S/ WETTENY JOSEPH		Executive Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)	February 14, 2023
Wetteny Joseph

/S/ MICHAEL B. MCCALLISTER		Chairman and Director	February 14, 2023
Michael B. McCallister

/S/ PAUL M. BISARO		Director	February 14, 2023
Paul M. Bisaro

/S/ VANESSA BROADHURST		Director	February 14, 2023
Vanessa Broadhurst

/S/ FRANK A. D'AMELIO		Director	February 14, 2023
Frank A. D’Amelio

/S/ SANJAY KHOSLA		Director	February 14, 2023
Sanjay Khosla

/S/ ANTOINETTE R. LEATHERBERRY		Director	February 14, 2023
Antoinette R. Leatherberry

/S/ GREGORY NORDEN		Director	February 14, 2023
Gregory Norden

/S/ LOUISE M. PARENT		Director	February 14, 2023
Louise M. Parent

/S/ WILLIE M. REED		Director	February 14, 2023
Willie M. Reed

/S/ LINDA RHODES		Director	February 14, 2023
Linda Rhodes

/S/ ROBERT W. SCULLY		Director	February 14, 2023
Robert W. Scully

99 |

Previous: Item 15. Exhibit and Financial Statement Schedules.